Medtronic plc (MDT)
After hours:
| Previous close | 85.92 |
| Open | 85.42 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 900 |
| Day's range | 84.45 - 85.85 |
| 52-week range | 68.84 - 91.00 |
| Volume | |
| Avg. volume | 5,993,380 |
| Market cap | 112.214B |
| Beta (5Y monthly) | 0.80 |
| PE ratio (TTM) | 26.83 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.76 (3.27%) |
| Ex-dividend date | 21 Mar 2024 |
| 1y target est | N/A |
- PR Newswire
MiniMed™ 780G system recognized among Fast Company's 2024 World Changing Ideas
Fast Company announced that the Medtronic MiniMed™ 780G automated insulin delivery system has been recognized in the Best World-Changing Idea, North America category as part of the 2024 World Changing Ideas Awards.
- PR Newswire
EuroPCR: Medtronic Evolut™ TAVR Platform Demonstrates Improved Quality of Life for Women with Severe Aortic Stenosis
Medtronic, the global leader in healthcare technology, today announced new data from the largest head-to-head comparative trial of transfemoral transcatheter aortic valve replacement (TAVR), the SMall Annuli Randomized To Evolut or SAPIEN (SMART) Trial, looking exclusively at women. The findings showed the Evolut self-expanding valve (SEV) was associated with significantly less bioprosthetic valve dysfunction (BVD) and improved quality of life for women with symptomatic severe aortic stenosis (A
- PR Newswire
Medtronic Affera™ Mapping and Ablation System with Sphere-9™ Catheter achieves endpoints for safety and efficacy, providing promising evidence for the future of atrial fibrillation treatment
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced positive results demonstrating excellent safety and efficacy of the Affera™ Mapping and Ablation System with Sphere-9™ Catheter, an all-in-one pulsed field (PF) and radiofrequency (RF) ablation and high density (HD) mapping catheter for the treatment of persistent atrial fibrillation (AFib). The SPHERE Per-AF study, a U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) pivotal trial, c
